ANALYSIS OF GSTP1 AND ABCB1 SINGLE-NUCLEOTIDE POLYMORPHISM IN CHILDREN WITH SOFT TISSUE AND BONE SARCOMAS
Abstract
Background. We analyzed the relationship between GSTP1 and ABCB1 single-nucleotide polymorphism and chemotherapy efficacy and toxicity in children with soft tissue and bone sarcomas. Methods. The study 58 children with high risks soft tissue and bone sarcomas included to the study. Genotyping of GSTP1 (105)Ile/(105)Val (rs1695) and ABCB1 3435C>T (rs1045642) were performed by genomic DNA extracted from blood mononuclear cells. Results. GSTP1 (105)Ile/(105)Val and ABCB1 3435C>T genotypes had no association with frequency or grade hematological toxicity. Patients with GSTP1 (105)Ile/(105)Val GG genotype had a greater risk of the disease recurrence and shorter diseasefree survival in comparison with AA genotype patients. Conclusion. Assessment of GSTP1 genotype may be important in selecting children suitable for chemotherapy.
About the Authors
Yu. A. Khochenkova
FSBI «N.N. Blokhin Russian Cancer Research Center» RAMS
Russian Federation
Russian Federation
R. N. Geidarov
FSBI science Engelhardt Institute of Molecular Biology Russian Academy of Sciences
Russian Federation
Russian Federation
E. E. Fesenko
Institute of cell Biophysics RAS
Russian Federation
Russian Federation
A. V. Shvarova
FSBI «N.N. Blokhin Russian Cancer Research Center» RAMS
Russian Federation
Russian Federation
N. M. Ivanova
FSBI «N.N. Blokhin Russian Cancer Research Center» RAMS
Russian Federation
Russian Federation
M. E. Abramov
FSBI «N.N. Blokhin Russian Cancer Research Center» RAMS
Russian Federation
Russian Federation
E. V. Stepanova
FSBI «N.N. Blokhin Russian Cancer Research Center» RAMS
Russian Federation
Russian Federation
References
1. Calhoun E.A., Chang C.H., Welshman E.E. et al. Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients. Oncologist. 2001, No. 6, p. 441-445.
2. Evans W.E., Relling M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999, No. 286, p. 487-491.
3. Evans W.E., Johnson J.A. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Ann. Rev. Genomics Hum. Genet. 2001, No. 2, p. 9-39.
4. Dervieux T., Meshkin B., Neri B. Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications. Mutat. Res. 2005, v. 573, p. 180-194.
5. Sarasqueta A., van Lijnschoten G., Lemmens V.E., Rutten H.J., van den Brule A.J. Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers? Mol. Diagn. Ther. 2011, v. 15, p. 277-283.
6. Watson M.A., Stewart R.K., Smith G.B., Massey T.E., Bell D.A. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis. 1998, v. 19, p. 275-280.
Review
For citations:
Khochenkova Yu.A., Geidarov R.N., Fesenko E.E., Shvarova A.V., Ivanova N.M., Abramov M.E., Stepanova E.V. ANALYSIS OF GSTP1 AND ABCB1 SINGLE-NUCLEOTIDE POLYMORPHISM IN CHILDREN WITH SOFT TISSUE AND BONE SARCOMAS. Bone and soft tissue sarcomas, tumors of the skin. 2012;(4):66-69. (In Russ.)
Views:
83
Email this article 
